Medpace (NASDAQ:MEDP) Raised to Hold at Leerink Partnrs

Medpace (NASDAQ:MEDP) was upgraded by stock analysts at Leerink Partnrs to a “hold” rating in a report released on Monday,Zacks.com reports.

MEDP has been the subject of several other reports. Robert W. Baird lifted their target price on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Leerink Partners initiated coverage on shares of Medpace in a report on Monday. They set a “market perform” rating and a $330.00 price target on the stock. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $376.30.

Medpace Trading Up 2.0 %

Shares of NASDAQ MEDP opened at $330.59 on Monday. The firm has a fifty day simple moving average of $337.29 and a two-hundred day simple moving average of $339.65. The firm has a market capitalization of $10.07 billion, a PE ratio of 26.17, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace has a 12 month low of $302.01 and a 12 month high of $459.77.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, sell-side analysts predict that Medpace will post 12.29 earnings per share for the current year.

Hedge Funds Weigh In On Medpace

Several institutional investors have recently made changes to their positions in MEDP. R Squared Ltd purchased a new stake in shares of Medpace in the 4th quarter worth $30,000. SBI Securities Co. Ltd. purchased a new stake in Medpace in the 4th quarter worth approximately $31,000. Stone House Investment Management LLC purchased a new position in Medpace during the third quarter valued at approximately $33,000. Jones Financial Companies Lllp raised its position in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after purchasing an additional 110 shares during the period. Finally, Lindbrook Capital LLC lifted its stake in shares of Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after buying an additional 29 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.